Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Dementia Risk Varies Significantly Among Racial And Ethnic Groups, Study Finds

By Drug Discovery Trends Editor | February 11, 2016

In the largest and longest study thus far of ethnic disparities in dementia risk, researchers compared six ethnic and racial groups within the same geographic population and found significant variation in dementia incidence among them. The results are published online in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association.

This is the first study to look at dementia risk in a large population representing the diversity of the United States. Researchers found dementia incidence to be highest in blacks and American Indian/Alaska Natives, lowest among Asian Americans, and intermediate among Latinos, Pacific Islanders and whites.

The researchers found that dementia incidence over the study period ranged from an average annual rate of 26.6 cases per 1,000 for blacks, and 22.2 cases per 1,000 for American Indians/Alaskan Natives, to 15.2 cases per 1,000 for Asian Americans. In between were Latinos and Pacific Islanders with an average annual rate of 19.6 cases per 1,000, and whites with 19.3 per 1,000.

Using cumulative risk estimates, researchers projected that among those who reach age 65 dementia-free, 38 percent of blacks, 35 percent of American Indians/Alaskan Natives, 32 percent of Latinos, 30 percent of whites, 28 percent of Asian Americans and 25 percent of Pacific Islanders would develop dementia in the next 25 years.

“Most research on inequalities in dementia includes only one to two racial and ethnic groups, primarily whites and blacks,” said lead author Elizabeth Rose Mayeda, Ph.D., postdoctoral fellow at University of California, San Francisco in the Department of Epidemiology and Biostatistics. “This is the only research that directly compares dementia for these six racial and ethnic groups, representing the true aging demographic of the United States in a single study population.”
Largest and Longest Study of Ethnic Disparities in Dementia

The study population included more than 274,000 northern California members of Kaiser Permanente, the nation’s largest private integrated healthcare system with more than 10 million members. The researchers used electronic health records covering patient visits over 14 years — from January 2000 through December 2013 — to identify participants diagnosed with dementia, as well as their race and ethnicity. The dementia diagnoses were Alzheimer’s, vascular dementia or non-specific dementia.

“Even in the lowest risk groups in the study, the lifetime risk of developing dementia is high — in every racial and ethnic group, over one in four people who survive to age 65 can expect to be diagnosed with dementia in their lifetime,” said Rachel Whitmer, Ph.D., the principal investigator of the study and a research scientist at the Kaiser Permanente Division of Research. Whitmer has an extensive research portfolio in aging epidemiology, specifically in predictors of cognitive decline and dementia, and population-level risk factors including metabolic, cardiovascular and inflammatory factors.

“This study has major public health implications. If all individuals aged 65 or older had the same rate of dementia as Asian Americans, 190,000 cases of dementia would be prevented annually,” Whitmer added. “These findings underscore the need to better understand risk factors for dementia throughout life to identify strategies to eliminate these inequalities.”

The researchers emphasize that while this study documents racial and ethnic disparities in dementia, the next step is to understand the mechanisms driving these inequalities.

“Based on the present study, we cannot determine the extent to which genetic or social and behavioral factors contribute to the observed patterns,” said Whitmer. “But if social and behavioral factors are the primary pathways, these findings suggest substantial reductions in dementia incidence are possible.”

Source: University of California San Francisco


Filed Under: Drug Discovery

 

Related Articles Read More >

Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE